Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

Maximum Days for Report: 14 days

Test: Metastatic Melanoma Panel by NGS

What are the prerequisites for the test Metastatic Melanoma Panel by NGS

  • FFPE tissue block with at least 20% tumor content
  • Requisition form with patient information
  • Pathology report with diagnosis of metastatic melanoma
  • Complete and signed informed consent form

What are the measure values for the test Metastatic Melanoma Panel by NGS

Gene Variant Measure Value
BRAF V600E Positive
NRAS Q61R Positive
KIT L576P Negative
TP53 R273H Positive

What does this test Metastatic Melanoma Panel by NGS identify?

Metastatic Melanoma Panel by NGS

This test uses Next-Generation Sequencing (NGS) technology to identify specific genetic mutations associated with metastatic melanoma. Metastatic melanoma is a type of skin cancer that has spread to other parts of the body, making it more difficult to treat.

The panel includes genes known to be involved in melanoma progression, such as BRAF, NRAS, and KIT. By analyzing these genes, the test can provide information about potential treatment options and prognosis for patients with metastatic melanoma.

Overall, the Metastatic Melanoma Panel by NGS helps oncologists personalize treatment plans and improve patient outcomes by targeting specific genetic mutations driving the cancer.

Why is this test Metastatic Melanoma Panel by NGS taken?

Metastatic Melanoma Panel by NGS Test

The Metastatic Melanoma Panel by NGS is conducted to help in the diagnosis and management of metastatic melanoma, a type of skin cancer that has spread to other parts of the body. This test uses Next-Generation Sequencing (NGS) technology to analyze multiple genes associated with melanoma, providing information on specific genetic mutations that may be driving the cancer.

By identifying these mutations, healthcare providers can tailor treatment options more effectively, such as targeted therapies or immunotherapies, based on the individual's genetic profile. This personalized approach can lead to better outcomes and improved quality of life for patients with metastatic melanoma.

No FAQs available.

Customer Google Rating